Severe apnea in an infant exposed to lamotrigine in breast milk.
OBJECTIVE
To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding.


METHODS
A 16-day-old infant developed several mild episodes of apnea that culminated in a severe cyanotic episode requiring resuscitation. A thorough examination at the hospital gave no evidence of underlying diseases that could explain the reaction. The mother had used lamotrigine in increasing doses throughout pregnancy, and at the time of the apneic episodes, she used 850 mg/day. The infant was fully breast-fed, and the neonatal lamotrigine serum concentration was 4.87 microg/mL at the time of admission. Breast-feeding was terminated, and the infant fully recovered.


CONCLUSIONS
Although there are several reports on extensive passage of lamotrigine into breast milk, this is the first published report of a serious adverse reaction in a breast-fed infant. Lamotrigine clearance increases throughout pregnancy, and maternal dose increases are often necessary to maintain therapeutic effect. After delivery, clearance rapidly returns to preconception levels, enhancing the risk of adverse reactions in both mothers and breast-fed infants if the dose is not sufficiently reduced. In this case, the dose was slowly reduced after delivery, and the maternal lamotrigine serum concentration more than doubled in the week before the neonatal apneic episodes. A high lamotrigine concentration was detected in the breast milk, and the neonatal lamotrigine serum concentration was in the upper therapeutic range. The neonatal lamotrigine elimination half-life was approximately twice that seen in adults. The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast-feeding in this infant.


CONCLUSIONS
Infants can be exposed to clinically relevant doses of lamotrigine through breast-feeding. Individual risk/benefit assessment is important, and close monitoring of both mother and child is advisable, especially during the first 3 weeks postpartum.
Nordmo
Elisabet
E
RELIS Nord-Norge (Regional Medicines Information Center of North Norway), University Hospital of North Norway Trust, Box 79, N-9038 Tromsø, Norway. elisabet.nordahl.nordmo@unn.no
Aronsen
Lena
L
Wasland
Kristin
K
Småbrekke
Lars
L
Vorren
Solveig
S
D000328:Adult; D001049:Apnea / Q000139:chemically induced* / Q000175:diagnosis* / Q000378:metabolism; D001942:Breast Feeding / Q000009:adverse effects*; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D000077213:Lamotrigine; D008297:Male; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy; D014227:Triazines / Q000009:adverse effects* / Q000378:metabolism
D014227:Triazines; D000077213:Lamotrigine